Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.97
-0.0500-2.48%
Volume:2.54M
Turnover:5.04M
Market Cap:679.65M
PE:-3.03
High:2.02
Open:2.01
Low:1.96
Close:2.02
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.65
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.56
PE(LYR):-2.28

Loading ...

Feb 25, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 15, 2020

Major Issues Report

8-K - Current report
Dec 07, 2020

Major Issues Report

8-K - Current report
Nov 04, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 04, 2020

Major Issues Report

8-K - Current report
Oct 26, 2020

Major Issues Report

8-K/A [Amend] - Current report
Aug 10, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 05, 2020

Major Issues Report

8-K - Current report
Jul 10, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 11, 2020

Major Issues Report

8-K - Current report
Jun 04, 2020

Major Issues Report

8-K - Current report
May 29, 2020

Major Issues Report

8-K - Current report
May 06, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 06, 2020

Major Issues Report

Current report, items 2.02 and 9.01